ARASAFE - a randomized, phase 3 trial comparing 3-weekly Docetaxel 75 mg/m2 (in a 3-week cycle) versus 2-weekly Docetaxel 50 mg/m2 (in a 4-week cycle) in combination with Darolutamide + ADT in patients with mHSPC
医学
多西紫杉醇
随机对照试验
内科学
泌尿科
化疗
作者
G. Von Amsberg,A. Roessler,Hendrik Heers,Florian Roghmann,Stephan Degener,Jozefina Casuscelli,Friedemann Zengerling,Marc‐Oliver Grimm